Polish Society of Vascular Surgery to feature sessions from ESVS, ASVS and ISES

305

From 22–24 May 2017, the IX Annual Congress of the Polish Society for Vascular Surgery (PTChN) will be held in the Hilton hotel in Warsaw, Poland. For the first time, the agenda includes special sessions with representatives of three international societies.

The IX Congress, chaired by the new president of the Society, Piotr Szopiński, is intended to respond to long-term challenges in the medical environment. With the PTChN strategy based on smart development, the society aims to merge the world of science and business, rendering the event an international platform for interchange of opinions and professional experience.

During the special sessions, the achievements of the representatives of the European Society for Vascular Surgery, the American Society for Vascular Surgery and the International Society of Endovascular Specialists will be presented.

“We have something to be proud of,” says Szopiński, responsible for the agenda of this year’s event. “Polish vascular surgery is at a very high, world level, the proof of which is the active membership of Polish surgeons in international societies. The June Congress will be the opportunity to present their achievements.”

The main topics of this year’s PTChN Congress will include peripheral arteries, carotid arteries and thoracic and abdominal aorta aneurysms. As with previous editions, additional time has been set aside in the agenda for panel discussions. The third day of the congress will be dedicated to presentation of the most interesting clinical cases. The agenda in this form is intended to enable detailed discussion of the matters tackled during the sessions, and to expand delegate’s knowledge of the said three vascular areas.

Due to the dynamic development of vascular surgery and low invasion techniques, the scientific committee have also included, for the first time, a special session called “Forum of New Technologies and Research”, with Prix Galien, a global medical and pharmaceutical industry competition, as its technical supervision partner. During the Forum, notable clinical tests will be presented, along with the projects submitted by the participants, in which new technologies were implemented.

LEAVE A REPLY